Welcome to our dedicated page for Stereotaxis Ord news (Ticker: STXS), a resource for investors and traders seeking the latest updates and insights on Stereotaxis Ord stock.
Stereotaxis, Inc. develops robotic technologies for minimally invasive endovascular intervention, with recurring news centered on electrophysiology and arrhythmia treatment. Company updates cover the MAGiC™ Magnetic Interventional Ablation Catheter, MAGiC Sweep high density mapping catheter, Genesis and GenesisX robotic magnetic navigation systems, and related clinical use in complex heart-rhythm procedures.
News also includes FDA and international regulatory clearances or approvals, hospital robotic heart-arrhythmia program launches, commercialization of cath-lab technologies such as Synchrony™ and SynX™, manufacturing and product-pipeline progress, material agreements, capital-structure updates, and periodic operating and financial results.
Stereotaxis (NYSE: STXS) reported 2025 results: revenue $32.4M (up 20% YoY) and Q4 revenue $8.6M (up 36% YoY). Recurring revenue was $22.2M (up 21%) and system revenue $10.2M (up 18%). Gross margin was ~53% for full year; cash was $13.4M with no debt.
Company highlighted US and EU approvals for GenesisX, MAGiC, and MAGiC Sweep and provided 2026 guidance targeting >$40M revenue and double-digit growth.
Stereotaxis (NYSE: STXS) will release fourth quarter and full year 2025 financial results on Monday, March 9, 2026 after U.S. market close and host a conference call and webcast at 4:30 p.m. ET.
Investors can dial in using U.S./Canada number 800-715-9871 or international 646-307-1963 with pass code 8365695, and a webcast and one-month phone replay will be available via the company investor relations site.
Stereotaxis (NYSE: STXS) announced a new robotic electrophysiology program at Klinikum Fürth in Fürth, Germany, making it the first hospital in Germany to adopt the Genesis Robotic Magnetic Navigation System for arrhythmia care. Physicians have treated initial patients across a range of arrhythmias using the system.
Company executives and Klinikum Fürth clinicians highlighted improved precision, procedural stability, and reduced radiation exposure from less fluoroscopic confirmation. Stereotaxis noted its technology has been used in over 150,000 patients globally and said it will support the hospital's robotic heart rhythm practice.
Stereotaxis (NYSE: STXS) announced FDA approval on January 6, 2026 of the MAGiC™ Magnetic Interventional Ablation Catheter for robotic cardiac electrophysiology procedures.
The MAGiC catheter is robotically navigated for mapping, diagnostic pacing, and creating endocardial lesions to treat supraventricular tachycardia in patients with congenital heart disease when conventional manual navigation is limited.
The company highlighted MAGiC's precision, expanded access for complex/underserved patients, and prior global use of Stereotaxis technology in over 150,000 patients.
Stereotaxis (NYSE: STXS) will participate in the Piper Sandler 37th Annual Healthcare Conference. David Fischel, chairman and CEO, will join a fireside discussion on December 3, 2025 at 9:00 AM ET and will be available for one-on-one investor meetings that day.
The release notes the company is achieving key regulatory milestones and showing early commercial growth. Stereotaxis develops robotic systems for minimally invasive endovascular intervention and reports its technology has been used to treat over 150,000 patients. The company included standard forward-looking risk disclosures about regulatory timing, market acceptance, and other business risks.
Stereotaxis (NYSE: STXS) reported results for the quarter ended September 30, 2025: total revenue $7.5M (Systems $1.9M; Recurring $5.6M). Gross margin was 55% (recurring 67%, systems 19%). Operating loss was $6.6M and net loss was $6.5M, with adjusted operating loss excl. non-cash charges of $2.5M. Negative free cash flow for Q3 was $4.2M. Cash on hand was $10.5M (pro forma $14.5M including an upcoming $4M financing tranche).
Operational highlights include FDA clearance for GenesisX, CE Mark and FDA submission for Synchrony, early commercial sales of MAGiC and MAGiC Sweep (>$300k revenue in first two months), and two Genesis orders in Europe. Company expects Q4 revenue >$9M and full-year 2025 revenue growth >20%.
Stereotaxis (NYSE: STXS) announced U.S. FDA 510(k) clearance for its new robotic system, GenesisX, on November 10, 2025. GenesisX preserves Robotic Magnetic Navigation while improving accessibility through built-in magnetic shielding, operation on standard 120/230V power, no structural anchoring, and an 80% smaller system cabinet, enabling installation in existing non-modified cath labs.
Stereotaxis has started a limited launch in the United States and Europe, is expanding compatible catheters and imaging compatibility, and is preparing supply chain, manufacturing, installation, and commercial processes for a full launch. GenesisX offers flexible capital models including sales, leases, and pay-per-use.
Stereotaxis (NYSE: STXS) will report its third quarter 2025 financial results on Tuesday, November 11, 2025 after the U.S. market close.
The company will host a conference call and webcast at 4:30 p.m. ET (1:30 p.m. PT) the same day to discuss results and corporate developments. Participants may dial 800-715-9871 (US/Canada) or 646-307-1963 (international) using pass code 4402192. A live and replay webcast will be available via the company’s investor relations website, and a phone replay will be available for one month beginning about four hours after the call.
Stereotaxis (NYSE: STXS) announced on Oct 15, 2025 that it obtained CE Mark in Europe and submitted a 510(k) application to the FDA for the Synchrony system, a platform designed to modernize interventional cath labs. Synchrony pairs a 55" 4K display with 1 frameSynX, a cloud app that the company says is HIPAA and GDPR compliant for remote connectivity, collaboration, recording, and monitoring. The company positions the platforms as foundational for future AI, remote procedures, and improved lab workflows.
Stereotaxis (NYSE: STXS) and CardioFocus announced a Collaboration Agreement on October 13, 2025 to advance a first‑ever robotic Pulsed Field Ablation (PFA) solution toward commercialization.
The collaboration pairs CardioFocus’ CE‑marked Centauri PFA system (used in >9,000 patients and reported in >40 publications) with Stereotaxis’ MAGiC catheter and Robotic Magnetic Navigation (RMN) platform (used in >150,000 patients and reported in >500 publications). Companies completed bench and pivotal preclinical studies showing safe, efficient, deep durable ventricular lesions and plan to move toward first‑human use, clinical trial initiation, regulatory compatibility work, and commercialization in the coming months.